Bosutinib

BNF:: 8.1.5
Status:: Do Not Prescribe (DNP), Red
Decision Date:: September 2016

Comments

RED:

NICE TA401: for previously treated chronic myeloid leukaemia. Is recommended within its marketing authorisation for treating Philadelphia-chromosome-positive chronic myeloid leukaemia. (NHSE commissioned). (Decision date - September 2016).

Do Not Prescribe (DNP):

NICE TA576: for untreated chronic myeloid leukaemia. (Terminated appraisal). (Decision date - May 2019).

NHS England drug. To be used in line with NHSE commissioning intentions.

Black Drug Classifications

6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)